- The company offers an innovative device that produces non-invasive HIFA treatment for prostate cancer with other applications to follow.
- Despite the pandemic and reimbursement which is yet to be settled, the company is still managing to sell these devices.
- An increasing installed base will increase the stream of revenue from consumables.
- The company isn’t bleeding cash and the shares are fairly cheap.
EDAP Set For Long-Term Growth
September 28th, 2020 · No Comments